DFCI's ASCO 2019 Update: Review of FDA's Approval of the First Targeted Agent for Metastatic Urothelial Carcinoma - FGFRi Erdafitinib
By
Dana-Farber Cancer Institute
FEATURING
Guru Sonpavde
By
Dana-Farber Cancer Institute
FEATURING
Guru Sonpavde
Login to view comments.
Click here to Login